Effect of Sublingual Immunotherapy on Antigen-Induced Bronchial and Nasal Inflammation in Mice

被引:10
作者
Kaminuma, Osamu [1 ,2 ]
Suzuki, Kazuya [2 ]
Mori, Akio [1 ]
机构
[1] Sagamihara Natl Hosp, Natl Hosp Org, Clin Res Ctr Allergy & Rheumatol, Kanagawa 2288522, Japan
[2] Tokyo Metropolitan Inst Med Sci, Dept Allergy & Immunol, Tokyo 113, Japan
关键词
Airway inflammation; Asthma; Neutrophils; Rhinitis; Sublingual immunotherapy; ALLERGEN IMMUNOTHERAPY; ASTHMA; MODEL;
D O I
10.1159/000312129
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Sublingual immunotherapy (SLIT) is effective in the treatment of a variety of allergic diseases, including bronchial asthma and rhinitis. However, how this local therapy exerts such wide effects is unclear. In this study, we comparatively examined the effect of SLIT on antigen-induced airway inflammation in bronchoalveolar and nasal cavities in mice. Methods: Mice were treated sublingually with ovalbumin (OVA) once a day for 2 weeks. Subsequently, they were immunized with the corresponding antigen. Following intratracheal and nasal challenge with OVA, infiltration of inflammatory cells into the bronchoalveolar and nasal cavities was investigated in these mice. Results: Massive infiltration of eosinophils as well as neutrophils into the bronchoalveolar cavity was induced by intratracheal OVA challenge. Eosinophils accumulated in the nasal cavity, but the number of neutrophils did not significantly change in response to nasal antigen challenge. These antigen-induced airway inflammatory responses, including the increases in the numbers of eosinophils and/or neutrophils in the bronchoalveolar and nasal cavities, were clearly suppressed by SLIT. Conclusions: This animal model displaying differential inflammatory responses in the bronchoalveolar and nasal cavities may be useful to elucidate the efficacy and mechanisms of SLIT against various allergic diseases. Copyright (C) 2010 S. Karger AG, Basel
引用
收藏
页码:75 / 78
页数:4
相关论文
共 14 条
[1]   Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites:: a double-blind, placebo-controlled study [J].
Bousquet, J ;
Scheinmann, P ;
Guinnepain, MT ;
Perrin-Fayolle, M ;
Sauvaget, J ;
Tonnel, AB ;
Pauli, G ;
Caillaud, D ;
Dubost, R ;
Leynadier, F ;
Vervloet, D ;
Herman, D ;
Galvain, S ;
André, C .
ALLERGY, 1999, 54 (03) :249-260
[2]   Allergen immunotherapy: Therapeutic vaccines for allergic diseases - A WHO position paper [J].
Bousquet, J ;
Lockey, R ;
Malling, HJ .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 102 (04) :558-562
[3]   Sublingual immunotherapy reduces allergic symptoms in a mouse model of rhinitis [J].
Brimnes, J. ;
Kildsgaard, J. ;
Jacobi, H. ;
Lund, K. .
CLINICAL AND EXPERIMENTAL ALLERGY, 2007, 37 (04) :488-497
[4]   Allergen immunotherapy and asthma: Efficacy, safety, and other considerations [J].
Cox, Linda .
ALLERGY AND ASTHMA PROCEEDINGS, 2008, 29 (06) :580-589
[5]   Sublingual immunotherapy: A comprehensive review [J].
Cox, Linda S. ;
Linnemann, Desiree Larenas ;
Nolte, Hendrik ;
Weldon, David ;
Finegold, Ira ;
Nelson, Harold S. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (05) :1021-1035
[6]  
FORDHUTCHINSON AW, 1990, CRIT REV IMMUNOL, V10, P1
[7]   Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model [J].
Foster, PS ;
Hogan, SP ;
Ramsay, AJ ;
Matthaei, KI ;
Young, IG .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (01) :195-201
[8]   Platelet-activating factor antagonists -: Current status in asthma [J].
Gómez, FP ;
Rodriguez-Roisin, R .
BIODRUGS, 2000, 14 (01) :21-30
[9]   Sublingual immunotherapy in sensitized mice [J].
Kildsgaard, Jens ;
Brimnes, Jens ;
Jacobi, Henrik ;
Lund, Kaare .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2007, 98 (04) :366-372
[10]   The role of chemokines in neutrophil biology [J].
Kobayashi, Yoshiro .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2008, 13 :2400-2407